Mechanisms for 5-HTT control of PPI and perseverative behavior using mouse models
使用小鼠模型研究 5-HTT 控制 PPI 和持续行为的机制
基本信息
- 批准号:7186087
- 负责人:
- 金额:$ 33.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-03-22 至 2012-02-29
- 项目状态:已结题
- 来源:
- 关键词:AcuteAgonistAllelesAnimal ModelAntidepressive AgentsAutistic DisorderBehaviorBehavioralBehavioral GeneticsBindingBrain regionChronicClassClomipramineCodeCognitiveCouplingDesipramineDiseaseDisruptionExhibitsFluoxetineGTP gamma SGenesGeneticGenetic ModelsHumanHypersensitivityInfusion proceduresKnock-outKnockout MiceLeadLinkLocalizedMeasuresMissense MutationMoclobemideModelingMonoamine Oxidase InhibitorsMotorMouse StrainsMusMutationNorepinephrineObsessive-Compulsive DisorderPopulationProtein OverexpressionPsyche structureReceptor ActivationReflex actionRegulationResearch PersonnelSelective Serotonin Reuptake InhibitorSensorySerotoninSerotonin Receptor 5-HT1BSpecificityStimulusTechniquesTestingTransgenic MiceTransgenic OrganismsWorkgain of functiongain of function mutationinhibitor/antagonistinsightmouse modelmutantneuromechanismnovelprepulse inhibitionpresynapticpreventpromoterreceptorreceptor bindingreceptor expressionresponsereuptakeserotonin transporteruptake
项目摘要
DESCRIPTION (provided by applicant): We propose to use behavioral and genetic mouse models to identify the neural mechanisms by which serotonin transporter (5-HTT) function modulates sensorimotor gating deficits and perseverative behaviors. Sensorimotor gating is a neural mechanism that filters excessive sensory, cognitive, and motor information, permitting mental and behavioral integration. Prepulse inhibition (PPI) is a form of startle plasticity that provides an operational measure of sensorimotor gating. Recent findings have implicated gain-of-function mutations in 5-HTT, and hypersensitivity of 5-HT1DP (homologous to mouse 5-HT1B) receptors, in two disorders characterized by deficient PPI and perseverative behaviors: obsessive-compulsive disorder (OCD) and autistic disorders. Only antidepressant drugs that potently block the reuptake of serotonin provide effective treatment for these disorders. Our recent findings in mice have identified a functional interaction between 5-HTT and 5-HT1B receptors in modulating PPI and perseverative behaviors. We found that the PPI deficits and perseverative behaviors induced by acute 5-HT1B agonist challenge are absent in 5-HTT knockout mice. We also found that the behavioral deficits induced by 5-HT1B agonists are absent in mice treated chronically, but not subchronically, with the selective serotonin reuptake inhibitor fluoxetine. Thus, we hypothesize that reducing 5-HTT function, genetically or pharmacologically, prevents the PPI deficits and perseverative behaviors induced by 5-HT1B receptor activation by desensitizing these receptors. We also hypothesize that increasing 5-HTT function, genetically or pharmacologically, will exacerbate the behavioral deficits induced by 5-HT1B receptor activation by sensitizing these receptors. Here, we propose to identify the mechanisms by which 5-HTT and 5-HT1B receptors interact to modulate these behaviors. First, we will test the hypothesis that potent blockade of 5-HTT is required to prevent 5-HT1B agonist-induced behavioral deficits by comparing the ability of different classes of antidepressants to reverse these effects. Second, we will assess 5-HT1B receptor expression and functional coupling to localize the brain regions in which 5-HT1B receptors are desensitized by antidepressant treatments. Third, we will generate two inducible transgenic mouse strains with increased 5-HTT function. One strain will overexpress mouse 5-HTT to evaluate the effects of increased 5-HTT availability, which may model the consequences of specific 5-HTT gene-linked polymorphic region (5-HTTLPR) alleles recently linked to OCD. The other strain will express human 5-HTT containing an uncommon mutation, Ne425Val, which renders 5-HTT constitutively active and was recently linked to OCD and autism. We hypothesize that both mouse strains will exhibit PPI deficits and perseverative behaviors, and increased behavioral responses to 5-HT1B agonists. Our unique approach could lead to novel animal models of the sensorimotor gating deficits and perseverative behaviors in OCD and autism.
描述(申请人提供):我们建议使用行为和遗传小鼠模型来确定5-羟色胺转运体(5-HTT)功能调节感觉运动、门控缺陷和持之以恒行为的神经机制。感觉运动门控是一种神经机制,它过滤过多的感觉、认知和运动信息,允许精神和行为的整合。预脉冲抑制(PPI)是惊恐可塑性的一种形式,它提供了一种感觉运动门控的操作措施。最近的发现表明,5-HTT的功能获得突变和5-HT1DP(与小鼠的5-HT1B同源)受体的超敏反应,与两种以PPI缺陷和持久性行为为特征的疾病有关:强迫症(OCD)和自闭症。只有能有效阻止5-羟色胺再摄取的抗抑郁药物才能有效治疗这些疾病。我们最近在小鼠身上的发现证实了5-HTT和5-HT1B受体之间在调节PPI和持久力行为方面的功能相互作用。我们发现,在5-HTT基因敲除小鼠中,不存在由急性5-HT1B激动剂激发引起的PPI缺陷和持久行为。我们还发现,在长期使用选择性5-羟色胺再摄取抑制剂氟西汀治疗的小鼠中,5-HT1B激动剂引起的行为缺陷是不存在的,但不是亚慢性治疗。因此,我们假设,降低5-HTT的功能,从基因或药物上,通过脱敏5-HT1B受体来防止PPI缺陷和5-HT1B受体激活引起的持久性行为。我们还假设,增加5-HTT的功能,从遗传学或药理学上,将加剧由5-HT1B受体激活引起的行为缺陷,通过敏化这些受体。在这里,我们建议确定5-HTT和5-HT1B受体相互作用来调节这些行为的机制。首先,我们将通过比较不同类别的抗抑郁药逆转5-HT1B激动剂诱导的行为缺陷的能力来检验这一假设,即需要有效地阻断5-HTT来防止5-HT1B激动剂诱导的行为缺陷。其次,我们将评估5-HT1B受体的表达和功能耦合,以定位5-HT1B受体被抗抑郁药物治疗脱敏的脑区。第三,我们将产生两个可诱导的5-HTT功能增强的转基因小鼠品系。一个品系将过度表达小鼠5-HTT,以评估5-HTT可用性增加的影响,这可能会模拟最近与强迫症有关的特定5-HTT基因连锁多态区域(5-HTTLPR)等位基因的后果。另一株将表达含有不常见突变Ne425Val的人类5-HTT,该突变使5-HTT具有结构性活性,最近被认为与强迫症和自闭症有关。我们假设,两个品系的小鼠都将表现出PPI缺陷和持久力行为,并对5-HT1B激动剂的行为反应增加。我们独特的方法可能导致强迫症和自闭症感觉运动门控缺陷和持之以恒行为的新动物模型。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEPHANIE C DULAWA其他文献
STEPHANIE C DULAWA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEPHANIE C DULAWA', 18)}}的其他基金
Dissecting the role of medial versus lateral orbitofrontal circuit activity in perseverative behavior
剖析内侧与外侧眶额回路活动在持续行为中的作用
- 批准号:
10665272 - 财政年份:2023
- 资助金额:
$ 33.09万 - 项目类别:
Novel mechanisms mediating the rapid antidepressant actions of glyoxylase 1 inhibitors
介导乙二醛酶 1 抑制剂快速抗抑郁作用的新机制
- 批准号:
10557209 - 财政年份:2022
- 资助金额:
$ 33.09万 - 项目类别:
Novel mechanisms mediating the rapid antidepressant actions of glyoxylase 1 inhibitors
介导乙二醛酶 1 抑制剂快速抗抑郁作用的新机制
- 批准号:
10351962 - 财政年份:2022
- 资助金额:
$ 33.09万 - 项目类别:
Translating OCD GWAS findings into mice: identifying epistatic modifiers of BTBD3
将 OCD GWAS 研究结果转化为小鼠:识别 BTBD3 的上位修饰因子
- 批准号:
8898917 - 财政年份:2014
- 资助金额:
$ 33.09万 - 项目类别:
Translating OCD GWAS findings into mice: identifying epistatic modifiers of BTBD3
将 OCD GWAS 研究结果转化为小鼠:识别 BTBD3 的上位修饰因子
- 批准号:
8773096 - 财政年份:2014
- 资助金额:
$ 33.09万 - 项目类别:
Mechanisms underlying fast-onset antidepressant effects of 5-HT2C antagonists - R
5-HT2C 拮抗剂快速起效抗抑郁作用的机制 - R
- 批准号:
8699844 - 财政年份:2013
- 资助金额:
$ 33.09万 - 项目类别:
Mechanisms underlying fast-onset antidepressant effects of 5-HT2C antagonists - R
5-HT2C 拮抗剂快速起效抗抑郁作用的机制 - R
- 批准号:
8579251 - 财政年份:2013
- 资助金额:
$ 33.09万 - 项目类别:
Mechanisms for 5-HTT control of PPI and perseverative behavior using mouse models
使用小鼠模型研究 5-HTT 控制 PPI 和持续行为的机制
- 批准号:
8012515 - 财政年份:2010
- 资助金额:
$ 33.09万 - 项目类别:
Mechanisms for 5-HTT control of PPI and perseverative behavior using mouse models
使用小鼠模型研究 5-HTT 控制 PPI 和持续行为的机制
- 批准号:
8038444 - 财政年份:2007
- 资助金额:
$ 33.09万 - 项目类别:
Mechanisms for 5-HTT control of PPI and perseverative behavior using mouse models
使用小鼠模型研究 5-HTT 控制 PPI 和持续行为的机制
- 批准号:
7571592 - 财政年份:2007
- 资助金额:
$ 33.09万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 33.09万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 33.09万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 33.09万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 33.09万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 33.09万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 33.09万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 33.09万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 33.09万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 33.09万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 33.09万 - 项目类别:














{{item.name}}会员




